CLICK HERE to learn more about Kineta's reverse merger with NASDAQ listed Yumanity Therapeutics (YMTX) and Effectiveness of Registration Statement on Form S-4

About Us

About Us

Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy.  Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies.

Kineta has established its immuno-oncology focused PiiONEER™ Platform aimed at developing fully human antibodies to address the major mechanisms of cancer immune resistance.  With drug candidates expected to enter the clinic and additional immuno-oncology assets in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.

Kineta has assembled an experienced management team, a seasoned research and development team, an immuno-oncology focused scientific advisory board, an enabling technology platform and a leading intellectual property position to advance its pipeline of potential novel immunotherapies for cancer patients.

“We aim to improve outcomes
for cancer patients
through our scientific innovation.”

                                           Shawn Iadonato — Kineta CEO

Leadership Team

Kineta is led by a team with diverse talents who are recognized for their expertise in drug development, corporate finance and success in bringing new pharmaceutical therapies to market.

Shawn Iadonato 21 – Mgmt

Shawn Iadonato, PhD

Chief Executive Officer

Craig Phillips 21

Craig Philips

President

Keith Baker 22

Keith Baker

Chief Financial Officer

Pauline Kenny 21

Pauline Kenny, JD

General Counsel

Thierry Guillaudeux, PhD 21

Thierry Guillaudeux, PhD

Chief Scientific Officer

Jacques Bouchy 21

Jacques Bouchy

EVP Investor Relations & Business Development

Molly Dorr 21

Molly Dorr

Head of Human Resources & Operations

Board of Directors

Scientific Advisory Board